Future pharmas may be increasingly specialized; Western vanity projected to drive cosmeceuticals;

> Expect pharma manufacturers may become increasingly specialized as they adopt strategies based on particular diseases related to specific systems in the human body or targeted populations. Analysis

> An aging population bent on maintaining its youth is expected to push U.S. demand for cosmeceuticals to 5.8% a year to reach $8.5 billion in 2015, projects Freedonia Group. Report

> The biggest challenge facing India in the food and drug industries is supply chain infrastructure, which "really needs to be overhauled for foreign players, contract manufacturing and cold-chain storage." Article

> Drug-delivery specialist OctoPlus wants you, if you're a specialty manufacturer of generics interested in controlled-release technology. Story

> BioAlliance Pharma will produce clinical batches of the orphan-designated Livatag (doxorubicin Transdrug), an injectable cytotoxin in nanoparticle form for a Phase III trial in liver cancer. Story

> Cadila Pharmaceuticals in Ethiopia anticipates international GMP certification from the Pharmaceutical Inspection Cooperation Scheme. Item

> Baxter in Europe has been named a "Great Place to Work" by the GPTW Institute. News

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.